Trial Profile
A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients Undergoing Major Cardiovascular Surgery
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Teprasiran (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Quark Pharmaceuticals
- 14 May 2014 New trial record